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Abstract Our previous studies have shown that the HMG-CoA
reductase inhibitor (HCRI) causes rhabdomyolysis and electrical
myotonia in rabbits and also kills L6 myoblasts in culture. In the
present study, we analyzed the intracellular signal transduction
pathway of HCRI-induced cell death using L6 myoblasts as a
model system. Here, we report that simvastatin, a lipophilic
HCRI, efficiently inhibited isoprenylation of Ras proteins and
therefore induced translocation of a significant part of Ras
proteins from the membrane fraction into the cytosolic fraction
within 10 min. With this translocation, PI 3-kinase activity of the
Ras-bound form both in total and in the membrane fraction was
also decreased profoundly. Furthermore, various PI 3-kinase
inhibitors also caused cell death with morphological changes
similar to those caused by simvastatin. These results might
represent the molecular events of HCRI-induced cell death, and
suggest the significance of PI 3-kinase activity of the Ras-bound
form in the maintenance of cell viability.
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1. Introduction
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitor (HCRI) is widely used for the treatment of
hypercholesterolemia [1,2]. It has been reported that HCRI
exerts adverse e¡ects, such as myopathy or rhabdomyolysis
[3^5]. In our in vivo studies using rabbits, we found that
simvastatin, a lipophilic HCRI, but not a hydrophilic
HCRI, induced electrical myotonia and rhabdomyolysis [6].
Because the rat L6 myoblast cell line is an established tool
for the investigation of myogenesis and di¡erentiation into
myotubes [7], we used this cell line as a model system for
simvastatin-induced damage on muscle cells. We found that
a lipophilic but not a hydrophilic HCRI kills the cells by a
mechanism involving intracellular Ca2 mobilization [8]. Our
subsequent study and others demonstrated that HCRI kills L6
myoblasts by an involving apoptotic cell death pathway
(manuscript in preparation and [9]).
Isoprenoids are essential for diverse cellular functions. Me-
valonate, a product of HMG-CoA reductase action, is a pre-
cursor of all isoprenoids. Lovastatin, a lipophilic HCRI, ef-
fectively blocks mevalonate synthesis and thereby protein
isoprenylation [10]. Lovastatin has also been found to block
cell cycling in G1 and G2/M phases of cells grown in vitro [11^
14], as well as suppressing growth of tumors in vivo [15,16].
These anti-mitogenic e¡ects of lovastatin are believed to be
due to the inhibition of isoprenoid synthesis [14^16]. Although
the precise mechanism of these anti-mitogenic e¡ects remains
unknown, the inhibition of isoprenylation of the oncogene
product p21 Ras and thereby the inhibition of the Ras-medi-
ated intracellular signaling pathway have been thought to be
responsible for these observed e¡ects [14,16].
Another cardinal intracellular signaling pathway for prolif-
eration and survival is the phosphatidylinositol 3-monosphos-
phate kinase (PI 3-kinase)-mediated pathway [17^19]. In neu-
ronal cells, this activity plays an important role in the
prevention of apoptotic cell death [19].
In this study, we examined the signal transduction pathway
of simvastatin-induced cell death in L6 myoblasts. We found
that simvastatin disturbed the posttranslational modi¢cation
of Ras proteins. This altered posttranslational modi¢cation of
Ras proteins seems to cause the inhibition of PI 3-kinase
activity in the Ras-bound form. These decrements in PI
3-kinase activity by HCRI appeared to be well correlated
with cell death, because wortmannin and LY294002, speci¢c
inhibitors of PI 3-kinase activity [20^22], also induced L6
myoblast cell death with morphological alterations similar
to those caused by simvastatin. These results suggest that
basal PI 3-kinase activity, especially the Ras-bound form,
might serve as a sensor of the initiation of the apoptotic cell
death program in the muscle cell system. When this form of
PI 3-kinase activity is lowered to below the threshold level, the
cells might commit suicide in such a cell system.
2. Materials and methods
2.1. Cell culture and treatment
L6 myoblasts (a generous gift from Dr. K. Nakahara, Kagoshima
University School of Medicine, Kagoshima, Japan) were cultured as
monolayers in culture dishes with DMEM containing 7.5% FBS,
100 U/ml penicillin and 100 Wg/ml streptomycin. Cells were treated
with various concentrations of simvastatin (a generous gift from San-
kyo Pharmaceutical Co., Ltd., Tokyo, Japan) for appropriate periods
of time at 37‡C. For morphological studies, L6 myoblasts were cul-
tured in 12-well culture plates. Cells were then treated with 30 Wg/ml
simvastatin as well as PI 3-kinase inhibitors (100 nM wortmannin or
2 WM LY294002) for 1 h at 37‡C. Moreover, 1 mM mevalonic acid, a
metabolite of HMG-CoA reductase, was added to the cells together
with simvastatin, and cells were similarly treated for 1 h at 37‡C.
These cells were examined by phase contrast microscopy and photo-
graphs of typical areas of each experiment were taken [23].
2.2. Survival rate of the cells
To examine the e¡ect of the addition of mevalonic acid to the
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culture medium on the survival rate of the cells, cells were treated with
1 mM mevalonic acid together with 30 Wg/ml simvastatin. After var-
ious times of incubation, cells were stained with 0.1% trypan blue
solution for 10 min at 37‡C. Photographs of all areas of each sample
were taken and the percentage of dead cells (stained) was calculated.
2.3. Immunoprecipitation and immunoblot analysis
After treatment, cells were rinsed with ice-cold PBS (phosphate-
bu¡ered saline) and lysed with lysis bu¡er (1% Nonidet P-40,
25 mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.1 mM sodium vanadate,
10% glycerol, 1 mM phenylmethylsulfonyl £uoride (PMSF), 1 Wg/ml
leupeptin) for 20 min on ice as previously described [24]. Insoluble
materials were removed by centrifugation at 12 000 rpm for 2 min at
4‡C. In each experiment, the amount of cell-free lysates was normal-
ized by protein content [25]. The lysate was incubated with an appro-
priate amount of anti-pan-Ras antibody (Oncogene Research Prod-
ucts, USA) with constant agitation at 4‡C, and Ras proteins were
recovered by incubating with protein G-agarose. The beads were
washed 3 times with lysis bu¡er and once with TBS (Tris-bu¡ered
saline), and suspended with the kinase reaction bu¡er (50 mM
HEPES, pH 7.4, 20 mM MnCl2, 5 mM MgCl2, 10 mM dithiothreitol
(DTT), 0.1 mM sodium vanadate). For immunoblot analysis, the
washed immunoprecipitates were subjected to SDS-polyacrylamide
gel electrophoresis. Resolved proteins were transferred to polyvinyli-
dene di£uoride (PVDF) membranes and probed with an anti-pan-Ras
antibody and a horseradish peroxidase-conjugated anti-mouse anti-
body using an enhanced chemiluminescence (ECL) detection system
(Amersham, UK) [24].
2.4. Subcellular fractionation
L6 myoblasts were homogenized using a glass homogenizer with
homogenization bu¡er (40 mM Tris-HCl, pH 7.5 containing 10 mM
MgCl2, 2 mM CaCl2, 250 mM sucrose, and 1 mM PMSF). Membrane
and cytosolic fractions were obtained by centrifugation at 200 000Ug
for 35 min in a Beckman TLA 100 [26].
2.5. Measurement of PI 3-kinase activity
The total cell-free lysate and the membrane fraction obtained as
FEBS 21077 9-11-98
Fig. 1. The morphology of L6 myoblasts treated with simvastatin, as well as with wortmannin or LY294002, two speci¢c inhibitors of PI 3-ki-
nase under phase-contrast microscopy. L6 myoblasts were cultured as described in Section 2 and exposed to 30 Wg/ml simvastatin (2), 100 nM
wortmannin (3), 2 WM LY294002 (4), or untreated (1) for 1 h at 37‡C. Both simvastatin and PI 3-kinase inhibitor-treated cells show cytoplas-
mic vacuolations and shrinkage of the cytoplasm. We also examined morphological changes in cells treated with 1 mM mevalonic acid together
with simvastatin (5). The ¢gure represents typical areas of three independent experiments. Magni¢cation U400.
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described above were incubated with an anti-pan-Ras antibody. PI
3-kinase activity of these Ras immunoprecipitates was assayed as
previously described [27]. Brie£y, Ras immunoprecipitates were pre-
incubated in 50 Wl of kinase reaction bu¡er at room temperature for
10 min using phosphatidylinositol (PI) as substrate. The assay was
initiated by the addition of 5 Wl of ATP solution (80 WM ATP and
2 mCi/ml [Q-32P]ATP) and incubated at 30‡C for 20 min. The reaction
was stopped by the addition of 100 Wl of chloroform-methanol-11.6 N
HCl (50:100:1). After centrifugation, the lower organic phase was
taken for the analysis by thin layer chromatography (TLC) on silica
gel plates (Polygram SIL N-NR, Macherey-Nagel, Germany) and the
TLC plates were developed in chloroform-methanol-25% ammonium
hydroxide-water (43:38:5:7). The plates were exposed to X-ray ¢lm at
370‡C with an intensifying screen for 16^24 h.
3. Results and discussion
Simvastatin, as well as PI 3-kinase inhibitors, caused mas-
sive vacuolations in the cytoplasm and shrinkage of the cell
body at 1 h after its addition to the culture medium, as illus-
trated in Fig. 1. On the other hand, the addition of mevalonic
acid to the culture medium partially blocked these simvasta-
tin-induced morphological changes. These data ware further
con¢rmed by trypan blue dye exclusion experiments. Only
48% of the cells treated with 30 Wg/ml simvastatin for 60 min
survived, whereas 74% of cells treated with mevalonic acid
together with simvastatin survived. Mevalonic acid under
the present condition was not toxic to L6 myoblasts (Fig.
1 (5) and Fig. 2). These data suggest the possible involvement
of HCRI-impaired mevalonate synthesis in the development
of cell death.
We next tried to elucidate the details of the intracellular
signaling pathway of the simvastatin-induced cell death. We
found that simvastatin rapidly inhibited normal maturation of
Ras proteins (Fig. 3). It caused the accumulation of non-pre-
nylated premature Ras in the cytosolic fraction within 10 min
after its addition to the culture medium (Fig. 3B). HCRI in-
hibits the synthesis of isoprenoids, which is important for the
isoprenylation of many proteins, including Ras proteins. The
isoprenylation of Ras proteins is thought to be an essential
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Fig. 2. E¡ect of simvastatin on the survival of L6 myoblasts. Cells
were treated with simvastatin and/or simvastatin plus mevalonic
acid and stained with 0.1% trypan blue solution to calculate the cell
survival rate. White dots represent control cells, black dots represent
cells treated with 30 Wg/ml simvastatin, while white squares repre-
sent cells treated with 1 mM mevalonic acid alone and black
squares represent cells treated with 1 mM mevalonic acid together
with simvastatin.
Fig. 3. E¡ect of simvastatin on the association of Ras proteins with
the plasma membranes. A: L6 myoblasts were treated with 30 Wg/
ml simvastatin for 10 min (S) or untreated (C). Then, Ras proteins
were immunoprecipitated with an anti-pan-Ras antibody from total
cell-free lysates, and subjected to immunoblot analysis with the
same antibody. The positions of p21Ras and non-processed p21Ras
(np p21Ras) are indicated on the right, and those of molecular
weight standards (in kDa) on the left. B: L6 cells were treated with
30 Wg/ml simvastatin for 5 min (2), 10 min (3), 30 min (4), or un-
treated (1). Then, cells were homogenized with homogenization bu¡-
er and fractionated as described in Section 2. 20 Wl of cytosolic frac-
tion (700 Wl) was boiled with SDS sample bu¡er and subjected to
the immunoblot analysis with an anti-pan-Ras antibody.
Fig. 4. E¡ects of simvastatin on PI 3-kinase activity in pan-Ras im-
munoprecipitates. A: PI 3-kinase activity in pan-Ras immunopreci-
pitates obtained from total cell-free lysates of the cells cultured in
the presence (2: 5 min, 3: 10 min) or absence (1) of 30 Wg/ml sim-
vastatin. PI 3-kinase activity was measured as described in Section
2. PIP represents phosphatidylinositol phosphate. B: PI 3-kinase ac-
tivity in pan-Ras immunoprecipitates prepared from the membrane
fraction. L6 cells were treated with 30 Wg/ml simvastatin for 5 min
(2), 10 min (3), or untreated (1). Then, cells were homogenized with
homogenization bu¡er and fractionated into cytosolic and mem-
brane fractions by ultracentrifugation, as described in Section 2.
After subcellular fractionation, pellets (the membrane fraction) were
lysed with lysis bu¡er for 20 min on ice, and Ras proteins were im-
munoprecipitated with an anti-pan-Ras antibody. The immunopreci-
pitates from the membrane fractions were assayed for PI 3-kinase
activity as described in Section 2. The radioactivity in each PIP spot
obtained by Cerenkov counting was follows: A1, 329 þ 26 cpm; A2,
135 þ 17 cpm; A3, 70 þ 13 cpm; B1, 283 þ 28 cpm; B2, 113 þ 14
cpm; B3, 61 þ 7 cpm (triplicate assay; mean þ S.D.).
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step in posttranslational modi¢cation for targeting Ras pro-
teins to the plasma membrane [28,29].
We next measured PI 3-kinase activity in the Ras immuno-
precipitates prepared from total cell-free lysates (Fig. 4A) and
from the membrane fraction of the cells (Fig. 4B), because a
previous study had shown that PI 3-kinase can be regulated
by the direct binding of the p110 catalytic subunit of PI 3-ki-
nase to the active form of Ras proteins [30]. The kinase
activity in Ras immunoprecipitates prepared from total cell-
free lysates and from the membrane fraction of the cells was
decreased drastically with simvastatin treatment (Fig. 4A,B).
This decrease in PI 3-kinase activity is not due to the loss of
cell viability, since none of the cells was stained with trypan
blue at 10 min after the addition of simvastatin. At this point,
we should bear in mind that naive L6 myoblasts exhibit an
appreciable high basal PI 3-kinase activity presenting as a
Ras-bound form under the present experimental conditions.
PI 3-kinase activity in Ras immunoprecipitates prepared from
the cytosolic fraction of naive cells was hardly detected (data
not shown). Therefore, it is reasonable to assume that in nor-
mal dividing cells, a part of PI 3-kinase activity might be
present in a Ras-bound form, especially localized in the mem-
brane fraction. These results suggest that simvastatin inhibits
the normal targeting of Ras proteins and therefore caused a
decrement of Ras proteins on the plasma membrane by de-
creasing isoprenylation. Therefore, PI 3-kinases might lose
their chance to bind to Ras proteins at the plasma membrane,
which in turn results in a reduction of the kinase activity.
Although we cannot exclude the possibility of a direct e¡ect
of simvastatin on PI 3-kinase activity in vivo, simvastatin did
not a¡ect PI 3-kinase activity in vitro (data not shown). Thus,
the present results strongly suggest that at least in L6 myo-
blasts, basal PI 3-kinase activity of the Ras-bound form,
which is localized in the membrane fraction, is important
for cell survival. Failure of this pathway might, at least in
part, play an important role in the development of cell death.
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